Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the ...

Palvella Therapeutics is set to expand Phase III SELVA trial to include subjects aged three to five years old.

Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...

Radiopharm Theranostics’ RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a ...

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate MZE829, in treating subjects with AKD ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Lilly has revealed that subjects with Crohn's disease have achieved long-term clinical and endoscopic outcomes with Omvoh in the VIVID-2.

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...